(Q43765205)

English

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Marcello Deraco

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Shigeki Kusamura

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

5

object named as

Antonio Macrì

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Salvatore Virzì

3

object named as

Salvatore Virzì

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

8

object named as

Serena Bonomi

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Domenico Rosario Iusco

9

object named as

Domenico Rosario Iusco

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Francesco Puccio

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Ciro Famulari

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Massimiliano Solazzo

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

0 references

publication date

12 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

122

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

215-220

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Interval debulking surgery for advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

The role of maintenance therapy and novel taxanes in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Peritonectomy procedures

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

"Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Advanced cytoreductive surgery in gynecologic oncology

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Intraperitoneal therapy for ovarian cancer: why has it not become standard?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.004

7 January 2021

Identifiers

10.1016/J.YGYNO.2011.05.004

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665254%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43765205&oldid=2103142491"